GlassScriptPhysician profile
Jeffrey Thomas Moore
NPI 1699497446
$6,266.51
in general payments reported to CMS, 2019-2025
22 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $427 · 2023: $2,296 · 2024: $2,076 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,754 · Education: $85.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,754.02 |
| Education | $85.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $989.61 | 2022-2025 | Caplyta |
| Abbvie INC. | $687.48 | 2023-2025 | |
| Corium, LLC | $556.57 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $546.63 | 2023-2025 | Abilify Mycite, Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $494.55 | 2022-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $440.38 | 2022-2025 | Fanapt, Hetlioz |
| Neos Therapeutics, LP | $331.50 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Alkermes, INC. | $314.17 | 2023-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $299.95 | 2023-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $262.09 | 2023-2025 | Auvelity, Sunosi |
| Noven Therapeutics, LLC | $233.38 | 2023-2025 | Xelstrym, Secuado |
| Tris Pharma INC | $219.35 | 2023-2025 | Quillivant, Quillichew Er, Dyanavel Xr |
| Bausch Health US, LLC | $164.52 | 2022-2024 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $154.99 | 2022-2025 | Austedo, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $153.75 | 2023-2024 | Invega Sustenna, Spravato, Invega |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $87.21 | 2024-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $85.83 | 2022-2025 | Quviviq, Quviviq |
| Almatica Pharma LLC | $68.18 | 2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $63.31 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $58.62 | 2022 | |
| Owp Pharmaceuticals, INC. | $30.90 | 2023 | Lamotrigine, Subvenite |
| Vertical Pharmaceuticals, LLC | $23.54 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.